Valuation: GlucoTrack, Inc.

Market Cap 1.9M 1.67M 1.55M 1.43M 2.68M 182M 2.73M 18.44M 7.22M 90.13M 7.14M 6.99M 311M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -2.03M -1.79M -1.66M -1.53M -2.87M -194M -2.92M -19.73M -7.72M -96.41M -7.64M -7.47M -333M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
84.22%
Yield 2024 *
-
Yield 2025 -
1 day+0.36%
1 week-18.64%
Current month-4.39%
1 month-2.24%
3 months-63.56%
6 months-91.06%
Current year-92.12%
1 week 0.28
Extreme 0.285
0.35
1 month 0.28
Extreme 0.285
0.63
Current year 0.28
Extreme 0.285
4.24
1 year 0.28
Extreme 0.285
14.14
3 years 0.28
Extreme 0.285
5,939.99
5 years 0.28
Extreme 0.285
39,000.04
10 years 0.28
Extreme 0.285
468,000.47
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-13
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 78 2024-06-13
Chairman 64 2024-02-12
Shariah Board Member 66 2025-01-27
Date Insider Type Main position Quantity % Market Cap.
3/26/25 Free

Director

4,490 0.0431%
3/25/25 Free

Director

8,747 0.0840%
3/25/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
-0.95%-18.64%-95.55%-99.98% 1.9M
+0.14%-0.85%-1.20%+11.73% 47.74B
-2.57%-0.06%+391.64%+612.50% 39.98B
-10.52%+3.49%+11.99%+46.50% 36.23B
+14.14%+21.65%+24.02%+8.45% 35.59B
-0.73%+2.78%+4.65%+41.16% 27.91B
+3.81%-0.70% - - 16.71B
-3.85%+8.15%+26.91%+125.65% 16.45B
+2.39%-3.63%-0.35%+10.34% 13.21B
+13.42%+7.95%-5.16%-28.66% 12.93B
Average +1.94%-0.07%+39.66%+80.85% 24.68B
Weighted average by Cap. +2.12%+2.95%+75.60%+130.48%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.83M -18.47M -16.99M -31.84M -2.16B -32.39M -219M -85.75M -1.07B -84.83M -83M -3.7B -19.39M -17.01M -15.84M -14.57M -27.32M -1.85B -27.79M -188M -73.58M -919M -72.79M -71.21M -3.17B
Net Debt -5.35M -4.7M -4.37M -4.02M -7.54M -511M -7.67M -51.87M -20.3M -253M -20.08M -19.65M -876M -3.94M -3.46M -3.22M -2.96M -5.55M -376M -5.64M -38.17M -14.94M -187M -14.78M -14.46M -644M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-07-28 US$0.3010 -0.95% 390,537
26-07-27 US$0.3039 +4.36% 246,338
26-07-24 US$0.2912 -6.76% 281,724
26-07-23 US$0.3123 +2.09% 345,189
26-07-22 US$0.3059 -18.40% 1,079,678
  1. Stock Market
  2. Stocks
  3. GCTK Stock